Danaher Corporation · NYSE:DHR
Danaher — Q1 2020 Earnings Presentation
15 slides from Danaher's earnings presentation, May 7, 2020
Slide 1: Danaher Corporation First Quarter 2020 Earnings Release
DANAHER CORPORATION First Quarter 2020 Earnings Release May 7, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated financial performance for the second quarter and full year 2020, and any other statements regarding events or developments that we anticipate will or
Slide 3: First Quarter 2020 Performance Summary
First Quarter 2020 Performance Summary +3.0% +6.0% Core +4.5% FX -1.5% ($ millions) Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions,” “Core,” and “FX,” please refer to the accompanying information required by Regulation G, located at the end of
Slide 4: First Quarter 2020 Performance Summary: Margins
First Quarter 2020 Performance Summary GROSS MARGINS Q1 2020 – 56.2% -100 BPS Q1 2019 – 55.8% +40 BPS Core +25 bps Acquisitions -5 bps Other -120 bps SG&A (as a % of Revenue) Q1 2020 – 33.6% Q1 2019 – 32.4% +120 BPS R&D (as a % of Revenue) Q1 2020 – 6.6% Q1 2019 – 6.3% +30 BPS Throughout this presen
Slide 5: First Quarter 2020 Performance Summary: Free Cash Flow
First Quarter 2020 Performance Summary FREE CASH FLOW PERFORMANCE ($ millions) +21.0% For the definition of Free Cash Flow, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" section of Danaher's website.
Slide 6: First Quarter 2020: Life Sciences
First Quarter 2020: Life Sciences +1.5% +70 BPS Core +2.5% Core +90 bps FX -1.0% Acquisitions -20 bps ($ millions) 6
Slide 7: First Quarter 2020: Diagnostics
First Quarter 2020: Diagnostics +6.0% +20 BPS Core +8.0% Core +50 bps FX -2.0% Other -30 bps ($ millions) 7
Slide 8: First Quarter 2020: Environmental & Applied Solutions
First Quarter 2020: Environmental & Applied Solutions +1.0% -70 BPS Core +2.5% Core -40 bps FX -1.5% Other -30 bps ($ millions) 8
Slide 9: Guidance
GUIDANCE 9
Slide 10: Q&A
Q&A 10
Slide 11: Danaher
DANAHER
Slide 12: Non-GAAP Reconciliations
Non-GAAP Reconciliations Adjusted Diluted Net Earnings Per Common Share from Continuing Operations 1 Core Revenue Growth Three-Month Period Ended % Change Three- Month Period Ended April 3, 2020 March 29, 2019 April 3, 2020 vs. Diluted Net Earnings Per Common Share from Continuing Operations (GAAP)
Slide 13: Non-GAAP Reconciliations
Non-GAAP Reconciliations Reconciliation of Operating Cash Flows from Continuing Operations (GAAP) to Free Cash Flow from Continuing Operations (Non-GAAP) Three Month Period Ended April 3, March 29, Year-over-Year 2020 2019 Change Cash Flows from Continuing Operations ($ in millions): Operating Cash
Slide 14: Non-GAAP Reconciliations
Non-GAAP Reconciliations Beginning with respect to forecasted results for the second quarter of 2020, we also present core revenue from continuing operations on a basis that includes revenue attributable to Cytiva (formerly the Biopharma Business of General Electric Company’s (“GE”) Life Sciences bu
Slide 15: Danaher
DANAHER